? The major goal of this proposal is to investigate glycated human CD59 as a surrogate bio-marker and predictor of vascular diabetic complications, with special focus on diabetic nephropathy and peripheral and cardio-vascular disease. CD59 is a key complement regulatory membrane protein that specifically inhibits formation of the membrane attack complex of complement (MAC), a transmembrane pore that triggers the release of growth factors and cytokines that stimulate cell proliferation, inflammation and thrombosis. Human CD59 is inactivated by glycation because it contains in its active site a glycation motif formed by amino acid residues K41-H44, as determined by NMR analysis of the human CD59 structure and site directed mutagenesis studies. We proposed that glycation-inactivation of CD59 leads first to increased MAC deposition in diabetic tissues and then to increased MAC-induced release of growth factors and cytokines that synergistically with other hyperglycemia induced pathways promote the diverse tissue damage responsible for the vascular complications that characterize human diabetes. Consistent with this hypothesis, glycated CD59 and activated complement proteins including MAC are found in glomeruli, nerves, blood vessels and failed vein grafts from diabetic but not from nondiabetic patients. Importantly, we have shown that a soluble form of CD59, both glycated and non-glycated, can be measured in human urine and plasma by established ELISAs. Glycated CD59 levels seem to correlate with the level of glycemic exposure. These extensive preliminary data make it imperative to assess whether glycated CD59 represents a pathogenically relevant biomarker of diabetic vascular complications. Specifically we will investigate whether glycated CD59 in plasma and/or urine identifies sub-populations at risk of developing vascular complications of diabetes (Specific Aim 1), discriminates persons with impaired glucose tolerance who have a higher risk of cardiovascular disease (Specific Aim 2), and predicts the risk of developing diabetic nephropathy (Specific Aim 3) and/or the risk of vein graft failure after peripheral by-pass surgery (Specific Aim 4). Successful accomplishment of these Specific Aims will provide a novel biomarker of diabetic vascular complications; it will also open new avenues for the early treatment and perhaps prevention of those diabetic complications. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK062994-03
Application #
6779849
Study Section
Special Emphasis Panel (ZRG1-MDCN-1 (05))
Program Officer
Jones, Teresa L Z
Project Start
2002-09-30
Project End
2006-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
3
Fiscal Year
2004
Total Cost
$710,837
Indirect Cost
Name
Harvard University
Department
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Liu, Fengming; Sahoo, Rupam; Ge, Xiaowen et al. (2017) Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice. J Diabetes Complications 31:311-317
Ghosh, Pamela; Luque-Fernandez, Miguel A; Vaidya, Anand et al. (2017) Plasma Glycated CD59, a Novel Biomarker for Detection of Pregnancy-Induced Glucose Intolerance. Diabetes Care 40:981-984
Ghosh, Pamela; Sahoo, Rupam; Vaidya, Anand et al. (2015) Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev 36:272-88
Denoyelle, Séverine; Chen, Ting; Yang, Hongwei et al. (2013) Synthesis and SAR study of novel 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as potent eIF2·GTP·Met-tRNAiMet ternary complex inhibitors. Eur J Med Chem 69:537-53
Ghosh, Pamela; Sahoo, Rupam; Vaidya, Anand et al. (2013) A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes. Am J Hematol 88:670-6
Soltys, Jindrich; Halperin, Jose A; Xuebin, Qin (2012) DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis. J Neuroimmunol 244:63-9
Cantel, S; Kavishwar, A; Schlimme, M et al. (2009) Glycated-CD59 antigen: exploration of synthetic approaches. Adv Exp Med Biol 611:317-8
Acosta, Juan; Qin, Xuebin; Halperin, Jose (2004) Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des 10:203-11
Qin, Xuebin; Krumrei, Nicole; Grubissich, Luciano et al. (2003) Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity 18:217-27